Skip to content

Effect of Vitamin E Fortified Whey Drink on Nutritional, Inflammatory and Oxidative Markers in Hemodialysis Patients

Effect of Vitamin E Fortified Whey Drink on Nutritional Status, Inflammatory Markers and Oxidative Stress in Hemodialysis Patients

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02163070
Acronym
EVEWD
Enrollment
92
Registered
2014-06-13
Start date
2013-09-30
Completion date
2014-06-30
Last updated
2015-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease

Keywords

whey protein, malnutrition, oxidative stress, hemodialysis

Brief summary

The purpose of the study is to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients

Detailed description

The aim of this interventional study was to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients. 92 hemodialysis patients were selected for the study. Inclusion criteria included: mean age of 17-65 years old; having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment; being dialyzed at least 2 times a week for 3 months. Exclusion criteria included: hospitalization in the last month; active infection; using immunosuppressant drugs or multi-vitamins; pregnancy. The Ethics Committee of Shiraz University of Medical Sciences reviewed and approved the protocol of this study.Informed consent were signed by all of them for participating in the study. Weight and height of the patients were recorded for BMI (body mass index) calculation. Then, all of the patients were assigned into 4 groups: 1. consumption of 220 milliliters of whey drink three times a week, 2. consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week, 3. consumption of 400 milligrams of vitamin E three times a week, 4. control group: no intervention. Patients were followed for 2 months. At the beginning and the end of the 2-month intervention period, 10 milliliters of blood were taken from all of the patients and nutritional status of the patients were assessed as the primary outcome. Serum levels of malondialdehyde, c-reactive protein, albumin, transferrin and lipoproteins were also measured. SGA, MIS and SF-12 questionnaires were filled for all of the patients at the beginning and the end of the study.

Interventions

DIETARY_SUPPLEMENTwhey drink,

consumption of 220 milliliters of whey drink three times a week,

DIETARY_SUPPLEMENTwhey drink fortified with vitaminE

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

DIETARY_SUPPLEMENTvitamin E

consumption of 400 milligrams of vitamin E three times a week,

Sponsors

Shiraz University of Medical Sciences
CollaboratorOTHER
Mohammad Hassan Eftekhari
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
17 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* mean age of 17-65 years old; * having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment; * be dialyzed at least 2 times a week for 3 months

Exclusion criteria

* hospitalization in the last month; * active infection; * using immunosuppressant drugs or multi-vitamins; * pregnancy, consuming whey or soy products

Design outcomes

Primary

MeasureTime frame
malnutrition (based on SGA assessment)2 months (8 weeks)
Malnutrition inflammation score2 months (8 weeks)

Secondary

MeasureTime frame
serum interleukin-62 months (8 weeks)
serum C-reactive protein2 months (8 weeks)
serum albumin2 months (8 weeks)
serum HDL-c2 months (8 weeks)
serum total cholesterol2 months (8 weeks)
serum triglyceride2 months (8 weeks)
serum transferrin2 months (8 weeks)
serum malondialdehyde2 months (8 weeks)
serum calcium2 months (8 weeks)
serum phosphate2 months (8 weeks)
quality of life2 months (8 weeks)
weight2 months (8 weeks)
height2 months (8 week)
Body mass index2 months (8 weeks)
serum creatinine2 months (8 weeks)
BUN (blood urea nitrogen)2 months (8 weeks)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026